Rallybio (RLYB) Competitors

Opus Genetics has a net margin of -892.36% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Opus Genetics' return on equity.

Opus Genetics presently has a consensus price target of $10.83, suggesting a potential upside of 166.18%. Given Opus Genetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Opus Genetics is more favorable than Rallybio.

In the previous week, Opus Genetics had 7 more articles in the media than Rallybio. MarketBeat recorded 7 mentions for Opus Genetics and 0 mentions for Rallybio. Opus Genetics' average media sentiment score of 0.14 beat Rallybio's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the media.

Opus Genetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, meaning that its stock price is 189% less volatile than the broader market.

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rallybio has lower revenue, but higher earnings than Opus Genetics. Rallybio is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Lexeo Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, suggesting that its stock price is 189% less volatile than the broader market.

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rallybio has higher revenue and earnings than Lexeo Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Lexeo Therapeutics had 6 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 0 mentions for Rallybio. Lexeo Therapeutics' average media sentiment score of 0.50 beat Rallybio's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Lexeo Therapeutics presently has a consensus target price of $20.14, suggesting a potential upside of 308.58%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Lexeo Therapeutics is more favorable than Rallybio.

Lexeo Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Lexeo Therapeutics' return on equity of -47.48% beat Rallybio's return on equity.

Larimar Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, indicating that its stock price is 189% less volatile than the broader market.

In the previous week, Larimar Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for Larimar Therapeutics and 0 mentions for Rallybio. Larimar Therapeutics' average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score.

Larimar Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Larimar Therapeutics' return on equity.

Rallybio has higher revenue and earnings than Larimar Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Larimar Therapeutics presently has a consensus target price of $15.29, suggesting a potential upside of 320.17%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Larimar Therapeutics is more favorable than Rallybio.

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rallybio has a beta of -0.89, meaning that its share price is 189% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for Rallybio. Rallybio's average media sentiment score of 0.00 equaled Enanta Pharmaceuticals'average media sentiment score.

Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 60.23%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Rallybio.

Rallybio has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Enanta Pharmaceuticals has a net margin of -89.56% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Enanta Pharmaceuticals' return on equity.